The antibody therapeutics field has been one of the most innovative arenas of biotechnology for decades. It is also one of the most crowded, but the structural characteristics of the IgE molecule offer a rich seam of new opportunities to make better antibodies.
Epsilogen is using protein engineering to mix and match individual epsilon chain domains with IgG gamma chain domains to build molecules that have the best characteristics of IgE and IgG. Epsilogen is also using glyco-engineering to manipulate IgE glycosylation patterns to improve PK and functionality.
